With 2024 as the year when the AOM market took shape, and 2026 a pivotal year that will define future competitive dynamics as the next wave of AOMs launch, and when the first off patent semaglutide likely becomes available in some countries, it is easy to dismiss 2025 as an uneventful transition
doi: 10.1016/j.tem.2010.06.005, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 28.Duarte AI, Moreira PI, Oliveira CR
At Intra-V, this may be provided as an IV drip or an IV push, depending on what is appropriate for you
The question was would they pause or would they be on pause, right
October 4, 2024: Large Number of Plaintiffs File Ozempic Lawsuits in September As of October 1, 2024, there were 1,090 cases pending in MDL 3092, Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation